Compare Abbott Laboratories (ABT) vs Archer-Daniels-Midland Co (ADM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Archer-Daniels-Midland Co — how do they compare? Abbott Laboratories trades at $95.46 (market cap $166.94B), while Archer-Daniels-Midland Co trades at $80.41 (market cap $37.69B). The key difference: Abbott Laboratories is far larger — about 4.4× Archer-Daniels-Midland Co's market cap, and Archer-Daniels-Midland Co pays the higher dividend (2.66%). Which is the better fit depends on your goals.
| ABT | ADM | |
|---|---|---|
Market Cap | $166.94B | $37.69B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $84.11 |
52-Week Low | $82.57 | $53.54 |
Enterprise Value | $193.69B | $47.72B |
Dividend Yield | 2.63% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →
